This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Olanzapine for Acute Headaches (Olanzapine)

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2016 by HealthPartners Institute
Sponsor:
Information provided by (Responsible Party):
HealthPartners Institute
ClinicalTrials.gov Identifier:
NCT03066622
First received: December 6, 2016
Last updated: August 2, 2017
Last verified: December 2016
  Purpose
This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.

Condition Intervention
Headache Drug: Standard of Care as per attending physician Drug: 5mg rapidly dissolving olanzapine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This is a prospective, randomized, convenience sample, feasibility trial to test for non-inferiority of oral rapidly dissolving olanzapine versus current emergency department standard of care in providing symptomatic relief to patients presenting with primary headache.
Masking: None (Open Label)
Masking Description:
Open label, not blinded, randomized 2-arm trial
Primary Purpose: Treatment
Official Title: Oral Rapidly Dissolving Olanzapine for Acute Primary Headache in the Emergency Department Setting: A Feasibility Trial

Resource links provided by NLM:


Further study details as provided by HealthPartners Institute:

Primary Outcome Measures:
  • Change in pain scores based on patient questionnaire [ Time Frame: 30 and 60 minutes post drug ingestion ]
    relief of primary acute headache


Secondary Outcome Measures:
  • Comparison of duration of ED length of stay [ Time Frame: Length of Emergency Department stay (Time Frame: up to 12 hours) ]
    Comparison of duration of ED length of stay when compared to current standard of care

  • Number of participants that receive peripheral intravenous catheterization [ Time Frame: Length of Emergency Department stay (Time Frame: up to 12 hours) ]
    Determining if patients randomized to rapidly dissolving Olanzapine eventually require IV access, defined as A successful cannulation (blood return or ability to infuse intravenous fluid without infiltration) on initial percutaneous needle puncture


Estimated Enrollment: 124
Actual Study Start Date: July 2016
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard of Care
IV Morphine or any medication per attending decision
Drug: Standard of Care as per attending physician
Patients are randomized to standard of care medication (as determined by attending physician)
Other Name: standard of care
Experimental: Olanzapine
oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
Drug: 5mg rapidly dissolving olanzapine
5mg rapidly dissolving olanzapine
Other Name: Zydis

Detailed Description:

Primary Question:

Does oral rapidly dissolving olanzapine provide efficacious analgesia in patients with acute headache of non-organic origin (primary headache) who come to the ED for abortive therapy when compared to current standard of care?

Secondary Aim:

Additionally, the study will aim to see if oral rapidly dissolving olanzapine decreases 1) duration of ED length of stay and 2) need for IV access when compared to the current standard of care.

This is a prospective, randomized, convenience sample, feasibility trial to test for non-inferiority of oral rapidly dissolving olanzapine versus current emergency department standard of care in providing symptomatic relief to patients presenting with primary headache.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Adult patient between 18-65 years of age presenting to the emergency department with acute primary headache
  2. Patient approved for inclusion by primary attending physician in the emergency department

Exclusion Criteria:

  1. Age < 18 or > 65
  2. Pregnancy
  3. Known allergy to olanzapine
  4. Known QT prolongation or underlying condition that places patient at risk for QT prolongation
  5. Inability to give written consent (intoxication, altered mental status)
  6. Headache of organic origin (trauma, infection, previous recent head or neck surgery)
  7. Patient already prescribed daily olanzapine on an outpatient basis
  8. Patient has been administered olanzapine within the past 24 hours
  9. Language barrier
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03066622

Contacts
Contact: Bradley Hernandez, MD 651-254-3108 bradley.s.hernandez@healthpartners.com
Contact: Sandi S Wewerka, MPH 651-254-5304 sandi.s.wewerka@healthpartneres.com

Locations
United States, Minnesota
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Bradley S Hernandez, MD    651-254-3108    bradley.s.hernandez@healthpartners.com   
Contact: Sandi S Wewerka, MPH    651-254-5304    sandi.s.wewerka@healthpartners.com   
Sponsors and Collaborators
HealthPartners Institute
Investigators
Principal Investigator: Bradley Hernandez, MD HealthPartners Institute
  More Information

Responsible Party: HealthPartners Institute
ClinicalTrials.gov Identifier: NCT03066622     History of Changes
Other Study ID Numbers: 16-420
Study First Received: December 6, 2016
Last Updated: August 2, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Headache
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Olanzapine
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents

ClinicalTrials.gov processed this record on September 19, 2017